Epizyme has entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct a clinical trial investigating the anti-cancer effects of Epizyme’s EZH2 inhibitor, tazemetostat, and Genentech’s recently approved anti-PD-L1 cancer immunotherapy, Tecentriq (atezolizumab). The study will evaluate this combination regimen for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma. Genent...